Definium Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Definium Therapeutics, Inc. carries a market capitalization of 2.57B, placing it among publicly traded companies globally. Its enterprise value stands at 1.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.57B |
| Enterprise Value | 1.43B |
Share Statistics
Definium Therapeutics, Inc. currently has 104.04M shares outstanding.
| Shares Outstanding | 104.04M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -2.67 |
| P/TBV Ratio | 6.81 |
| P/FCF Ratio | -12.19 |
| P/OCF Ratio | -12.19 |
Financial Position
Definium Therapeutics, Inc. maintains a current ratio of 4.69, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.62, indicating elevated leverage, while an interest coverage ratio of -31.57 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.69 |
| Quick Ratio | 4.60 |
| Debt / Equity | 14.62 |
| Debt / EBITDA | -0.21 |
| Interest Coverage | -31.57 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -70.22 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Definium Therapeutics, Inc.'s stock has gained approximately 206.76203% over the past 52 weeks. The 50-day moving average sits at 14.26, while the 200-day moving average is 14.26.
| Beta (5Y) | N/A |
| 52-Week Price Change | 206.76203% |
| 50-Day Moving Average | 14.26 |
| 200-Day Moving Average | 14.26 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -193.37M, while operating income came in at -193.37M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -193.37M |
| Pretax Income | -237.54M |
| Net Income | -237.54M |
| EBITDA | -193.37M |
| EBIT | -193.37M |
| Earnings Per Share (EPS) | -2.54 |
Balance Sheet
Definium Therapeutics, Inc. holds 373.42M in cash and equivalents against 40.77M in total debt, resulting in a net debt position of -221.74M. Total book value stands at -659.77M, with working capital of 299.45M providing operational flexibility.
| Cash & Cash Equivalents | 373.42M |
| Total Debt | 40.77M |
| Net Debt | -221.74M |
| Equity (Book Value) | -659.77M |
| Book Value Per Share | -7.07 |
| Working Capital | 299.45M |
Cash Flow
Definium Therapeutics, Inc. produced -144.77M in operating cash flow over the past twelve months.
| Operating Cash Flow | -144.77M |
| Capital Expenditures | N/A |
| Free Cash Flow | -144.77M |
| FCF Per Share | -1.55 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -15.39 |
| FCF Yield | -8.21 |
Stock Splits
Definium Therapeutics, Inc.'s most recent stock split took place on August 29, 2022 with a 15:1 split ratio.
| Last Split Date | 8/29/2022 |
| Split Ratio | 15:1 |
Scores
Definium Therapeutics, Inc. posts an Altman Z-Score of 5.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.49 |